These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19570737)

  • 1. Bisphosphonate-associated adverse events.
    Papapetrou PD
    Hormones (Athens); 2009; 8(2):96-110. PubMed ID: 19570737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of bisphosphonates: current issues.
    Diel IJ; Bergner R; Grötz KA
    J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and potential risks of bisphosphonate therapy A narrative review.
    El Osta L; El Osta N; El Osta H
    J Med Liban; 2016; 64(4):228-37. PubMed ID: 29845849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of long-term bisphosphonate therapy for the management of osteoporosis.
    Lewiecki EM
    Drugs; 2011 Apr; 71(6):791-814. PubMed ID: 21504254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intravenous bisphosphonates in osteoporosis.
    Civitelli R; Napoli N; Armamento-Villareal R
    Curr Osteoporos Rep; 2007 Mar; 5(1):8-13. PubMed ID: 17320022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of bisphosphonates.
    Orozco C; Maalouf NM
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular Side Effects of Bisphosphonates: A Review of Literature.
    Chartrand NA; Lau CK; Parsons MT; Handlon JJ; Ronquillo YC; Hoopes PC; Moshirfar M
    J Ocul Pharmacol Ther; 2023; 39(1):3-16. PubMed ID: 36409537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonates treatment in patients with osteoporosis].
    Rizzoli R
    Ther Umsch; 2012 Mar; 69(3):173-81. PubMed ID: 22403110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bisphosphonate-associated osteonecrosis of the jaws 1].
    Allard RH; Lips P; Eekhoff EM; van Merkesteyn JP; van der Waal I
    Ned Tijdschr Tandheelkd; 2007 Oct; 114(10):423-7. PubMed ID: 17972610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
    Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW
    Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.